R&Q Insurance Holdings



Discussions underway to unlock value

4 July 2023

The investment case pivots on the progress of strategic options under consideration for the two operating businesses. Specifically, these relate to the outcome of discussions with potential buyers for each entity, a process which has been simplified by their legal separation. We see potential scope to realise a net return above R&Q's current market value.

Initial discussions focus on Accredited, R&Q's program management business for which it confirms receipt of interest from a number of parties. Accredited is estimated to be the second largest program manager globally with operations in both the US and UK/Europe.

Exploring strategic options

To recap, in April R&Q announced the decision to evaluate strategic options for its businesses and in Q2 completed their legal separation. These two operations, Accredited (program management) and R&Q Legacy are well-established and competitively positioned, have undergone significant internal transformation and restructuring, and have capital bases required to operate independently. Accredited's status as a standalone insurance industry counterparty was recently confirmed via its AM Best (A- financial strength) rating.

- Accredited no longer relies on the group balance sheet for its financial strength rating. Margin
 improvement (from 36% to 57%) reflects scale (GWP US\$1.8bn) and greater operational
 efficiency. This business has the size and reputation to continue to grow towards its full potential.
- R&Q Legacy has developed more slowly than expected but continues its planned transition into
 a more capital efficient business. Its capital base was recently boosted by US\$50-60m of
 preferred equity raised by the group. FY22 did, however, include US\$32m of adverse
 development, mainly related to older transactions.

Sum of the parts seen above current market cap

A possible valuation template for program managers has been provided by transactions such as Markel's acquisition of State National (2017) and Mitsui Sumitomo's acquisition of Transverse Group (2023), both concluded at multiples above 10x EBITDA (undisclosed, according to industry sources).

Accredited is a high potential, fast-growing business. A sum of the parts based on its sale achieving the above multiples (net of FY22 US\$345m group net debt) should more than cover the current group market cap (c US\$244m) and enable R&Q to separately consider various options for Gibson Re (R&Q Legacy), including a potential trade sale.

Summary FY22 results			
Year end 31 Dec, US\$m unless stated	2020	2021 Restated	2022
Group Pre-Tax Op. Profit	20.6	(21.4)	(33.3)
PM Fee Income (incl. minority stake)	24.1	56.1	98.0
PM PTOP	3.3	20.6	55.7
Legacy Insurance PTOP	49.0	(6.1)	(56.6)
EPS (c)	17.5	(46.8)	(91.3)

Source: R&Q report & accounts

Company Data

 EPIC
 RQIH

 Price
 52p

 52 weeks Hi/Lo
 111p/44p

 Market cap
 £193m



Description

R&Q Insurance Holdings Ltd is a long-established UK and US insurance business, led by experienced management.

It is focused on two core strategies:

Program Management (PM) is a fully regulated commission fee-based business, which acts as a conduit between reinsurers and MGAs (insurance distributors).

Legacy Insurance provides exit solutions for legacy/run-off insurance assets to vendors in the US, Europe, and Bermuda

Roger Leboff (Analyst) 0207 065 2690 roger@equitydevelopment.co.uk

Andy Edmond

0207 065 2691 andy@equitydevelopment.co.uk



Two high potential businesses requiring further investment

Both entities' transformations are ongoing, and R&Q has committed to further investment to upgrade and rationalise technology, people, risk management and governance cultures.

Both look well placed to grow as they evolve and build further scale to compete independently, but views on intrinsic value are impacted by a challenging FY22 for R&Q Legacy and volatile markets generally.

R&Q Legacy continuing transition in softer pricing market

The unexpected US\$32m adverse development in older legacy books was a major source of R&Q Legacy's disappointing headline US\$56.6m pre-tax operating loss, but the comparative also reflects the transition to a capital efficient model based upon annual recurring, fee-based revenue vs a balance sheet intensive, day-one gain structure.

FY22 Fee Income was US\$12.1m (FY21: nil). FY22 saw four transactions for US\$68m of Gross Reserves Acquired, a 91% fall vs 2021 due to extra prudence in a softer pricing market. Period end RUM was US\$396m (FY21: US\$417m), but that increased to over US\$1bn post the MSA Safety transaction involving non-insurance liabilities which closed in January 2023.

Summary Financial Performance, y-o-y					
(US\$m, except where noted), y/e 31 Dec	2022	2021	Change		
Accredited					
Gross Written Premium	1.8bn	1.0bn	+76%		
Fee Income	80.0	44.9	+78%		
Pre-Tax Operating Profit	55.7	20.6	+170%		
PTOP Margin	56.8%	35.7%			
R&Q Legacy					
Gross Reserves Acquired	68.8	735.0	-91%		
Reserves Under Management	395.6	417.0	-5%		
Fee Income	12.1	0.0			
Pre-Tax Operating (Loss)	(56.6)	(6.1)			
Corporate / Other					
Net Unallocated Expenses	(1.9)	(13.2)	-86%		
Interest Expense	(30.5)	(22.7)	+34%		
<u>Group</u>					
Fee Income (excl. MGA stakes)	92.0	44.9	-105%		
Pre-Tax Operating (Loss)	(33.3)	(21.4)	+55%		
Operating (Loss) / share	(9.9)c	(7.5)c	+32%		

Source: R&Q FY22 results



Contacts

Andy Edmond

Direct: 020 7065 2691 Tel: 020 7065 2690 andy@equitydevelopment.co.uk

Hannah Crowe

Direct: 0207 065 2692 Tel: 0207 065 2690 hannah@equitydevelopment.co.uk

Equity Development Limited is regulated by the Financial Conduct Authority

Disclaimer

Equity Development Limited ('ED') is retained to act as financial adviser for its corporate clients, some or all of whom may now or in the future have an interest in the contents of this document. ED produces and distributes research for these corporate clients to persons who are not clients of ED. In the preparation of this report ED has taken professional efforts to ensure that the facts stated herein are clear, fair and not misleading, but makes no guarantee as to the accuracy or completeness of the information or opinions contained herein.

This document has not been approved for the purposes of Section 21(2) of the Financial Services & Markets Act 2000 of the United Kingdom ('FSMA'). Any reader of this research should not act or rely on this document or any of its contents. This report is being provided by ED to provide background information about the subject of the research to relevant persons, as defined by the Financial Services and Markets Act 2000 (Financial Promotions) Order 2005. This document does not constitute, nor form part of, and should not be construed as, any offer for sale or purchase of (or solicitation of, or invitation to make any offer to buy or sell) any Securities (which may rise and fall in value). Nor shall it, or any part of it, form the basis of, or be relied on in connection with, any contract or commitment whatsoever.

Research produced and distributed by ED on its client companies is normally commissioned and paid for by those companies themselves ('issuer financed research') and as such is not deemed to be independent as defined by the FCA, but is 'objective' in that the authors are stating their own opinions. This document is prepared for clients under UK law. In the UK, companies quoted on AIM are subject to lighter due diligence than shares quoted on the main market and are therefore more likely to carry a higher degree of risk than main market companies.

ED may in the future provide, or may have in the past provided, investment banking services to the subject of this report. ED, its Directors or persons connected may at some time in the future have, or have had in the past, a material investment in the Company. ED, its affiliates, officers, directors and employees, will not be liable for any loss or damage arising from any use of this document, to the maximum extent that the law permits.

More information is available on our website www.equitydevelopment.co.uk

Equity Development, 16 -18 Finsbury Circus, London EC2M 7EB

Contact: info@equitydevelopment.co.uk | 020 7065 2690